Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group.

Twenty-one evaluable patients with advanced carcinoma of the endometrium were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Twelve had received prior chemotherapy. Seven patients had stable disease; 14 had increasing disease. There were two life-threatening toxic episodes. Aminothiadiazole used in this dosage and schedule has negligible activity in previously treated patients with carcinoma of the endometrium.